Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Yield and Characterisation of CFT in ANOCA
Author(s): Johanna McChord , Astrid Hubert , Udo Sechtem , et al Added: 1 year ago

Prevention & Chronic Conditions
CardioNerds @AHA23: ORBITA-2: PCI for Stable Angina
Author(s): Rasha Al-Lamee , Christopher Rajkumar , Nazli Okumus Added: 2 years ago
AHA 2023 — Investigators of ORBITA-2 trial, Dr Rasha Al-Lamee and Dr Christopher Rajkumar (Imperial College London, UK) talked with CardioNerds Ambassador, Dr Nazli Okumus about the randomised, placebo-controlled trial (NCT03742050) that compared the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy at 12 weeks.The ORBITA… View more

Intervention
Left Main Disease: The Last Frontier for Medical Therapy in Stable CAD?
Author(s): Armin Arbab-Zadeh , Michelle Graham , Hector M Garcia-Garcia , et al Added: 7 months ago

Intervention

Prevention & Chronic Conditions
Antithrombotics in stable CAD and AF
Author(s): Massimo Grimaldi , Bianca Rocca Added: 1 month ago

Anticoagulation

Electrophysiology & Arrhythmia
Non-invasive Coronary Functional Tests in ANOCA
Author(s): Nello Cambise , Angelo Giuseppe Marino , Fabio De Benedetto , et al Added: 2 months ago

Imaging & Diagnostics

Prevention & Chronic Conditions
Author(s): Rasha Al-Lamee , Michael Foley Added: 2 years ago
ACC.24 — Investigators, Dr Rasha K Al-Lamee and Dr Michael Foley (Imperial College London, UK) joined us to discuss the ORBITA COSMIC trial (NCT04892537).This randomized, double-blinded, placebo-controlled trial investigated the effects of coronary sinus reducer (CSR) as compared to placebo on myocardial perfusion via MRI, exercise duration, and symptoms in patients with refractory angina and… View more

Prevention & Chronic Conditions
ACC 25: The EKSTROM Trial
Author(s): Matthew J Budoff Added: 1 year ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more

Intervention
Research Area(s) / Expertise:
Prof Stables is consultant cardiologist at LHCH — a specialist cardiothoracic unit and, in terms of procedure volume, one of the largest cardiac units in Europe. Prof Stables was the Chair of the Academic and Research Committee at the British Cardiovascular Society. View more
Author(s): Evan A Stein Added: 2 years ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period… View more

Prevention & Chronic Conditions
Separated Vasoreactivity Testing of ACH
Author(s): Shozo Sueda , Tomoki Sakaue Added: 1 year ago

Prevention & Chronic Conditions